Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results

Bob Löwenberg • 24 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Azacitidine
HOVON-97

The HOVON-97 study (Netherlands Trial Registry NTR1810; EudraCT 2008-001290-15) investigated the use of azacitidine maintenance following intensive chemotherapy in older patients with acute myeloid leukemia (AML). We spoke to Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, about the recently published results. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Bob Löwenberg

1:28
Bob Löwenberg's perspective on CAR-T and immunotherapy for AML
Bob Löwenberg • 24 Feb 2019
3:46
Developments in newly diagnosed AML therapy in Europe: inspiring cooperation for tailored treatment
Bob Löwenberg • 24 Feb 2019
3:18
How can we tackle treatment failure in ALL?
Bob Löwenberg • 16 Apr 2018
4:57
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications
Bob Löwenberg • 19 Feb 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals